Starpharma Holdings Limited (SPHRY)
OTCMKTS
· Delayed Price · Currency is USD
0.6200
+0.0300 (5.08%)
Apr 24, 2025, 4:00 PM EDT
Starpharma Holdings Revenue
Starpharma Holdings had revenue of 2.43M AUD in the half year ending December 31, 2024, with 41.85% growth. This brings the company's revenue in the last twelve months to 4.16M, down -60.98% year-over-year. In the fiscal year ending June 30, 2024, Starpharma Holdings had annual revenue of 9.76M with 124.64% growth.
Revenue (ttm)
4.16M AUD
Revenue Growth
-60.98%
P/S Ratio
9.25
Revenue / Employee
103.95K AUD
Employees
40
Market Cap
23.81M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 9.76M | 5.41M | 124.64% |
Jun 30, 2023 | 4.34M | -819.00K | -15.87% |
Jun 30, 2022 | 5.16M | 1.68M | 48.04% |
Jun 30, 2021 | 3.49M | -3.63M | -50.99% |
Jun 30, 2020 | 7.12M | 4.40M | 161.58% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Starpharma Holdings News
- 1 year ago - Starpharma: Patience Needed, But A Lot To Like - Seeking Alpha
- 2 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 2 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 3 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 3 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 3 years ago - Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma - Seeking Alpha
- 4 years ago - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack - Seeking Alpha
- 4 years ago - Starpharma Up With News, Down With None; Timing Entry Makes Sense - Seeking Alpha